ReviewClinical and experimental immunology2016
The case for an autoimmune aetiology of type 1 diabetes.
Review in Clinical and experimental immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Heterogeneity between insulin and proinsulin in the potency for insulin autoantibodies in newly diagnosed type 1 diabetes children.Clinical and experimental immunology · 2026Article
- Current and Emerging Assays for Measuring Human T-Cell Responses Against Beta-Cell Antigens in Type 1 Diabetes.Biomolecules · 2025Review
- Proinsulin C-peptide is a major source of HLA-DQ8 restricted hybrid insulin peptides recognized by human islet-infiltrating CD4PNAS nexus · 2024Article
- An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes.Diabetes · 2024Article
- Charting Peptide Shared Sequences Between 'Diabetes-Viruses' and Human Pancreatic Proteins, Their Structural and Autoimmune Implications.Bioinformatics and biology insights · 2024Article
- Article
- Lentinan confers protection against type 1 diabetes by inducing regulatory T cell in spontaneous non-obese diabetic mice.Nutrition & diabetes · 2023Article
- Affinity purification of serum-derived anti-IA-2 autoantibodies in type 1 diabetes using a novel MBP-IA-2 fusion protein.Biochemistry and biophysics reports · 2023Article
- Monitoring immunomodulation strategies in type 1 diabetes.Frontiers in immunology · 2023Review
- Glutamine deamidation does not increase the immunogenicity of C-peptide in people with type 1 diabetes.Journal of translational autoimmunity · 2023Article
- Engineered Extracellular Vesicles in Treatment of Type 1 Diabetes Mellitus: A Prospective Review.Biomedicines · 2022Review
- Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.European journal of immunology · 2022Article
- The Contribution of Neutrophils and NETs to the Development of Type 1 Diabetes.Frontiers in immunology · 2022Review
- Calcitonin gene-related peptide is a potential autoantigen for CD4 T cells in type 1 diabetes.Frontiers in immunology · 2022Article
- Article
- Identifying New Hybrid Insulin Peptides (HIPs) in Type 1 Diabetes.Frontiers in immunology · 2021Review
- Proinsulin-specific T-cell responses correlate with estimated c-peptide and predict partial remission duration in type 1 diabetes.Clinical & translational immunology · 2021Article
- Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice.Frontiers in immunology · 2021Article
- Modeling Type 1 Diabetes Using Pluripotent Stem Cell Technology.Frontiers in endocrinology · 2021Review
- IL-17F induces inflammation, dysfunction and cell death in mouse islets.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) develops when there are insufficient insulin-producing beta cells to maintain glucose homeostasis. The prevailing view has been that T1D is caused by immune-mediated destruction of the pancreatic beta cells. However, several recent papers have challenged the long-standing paradigm describing T1D as a tissue-specific autoimmune disease. These authors have highlighted the gaps in our knowledge and understanding of the aetiology of T1D in humans. Here we review the evidence and argue the case for the autoimmune basis of human T1D. In particular, recent analysis of human islet-infiltrating T cells brings important new evidence to this question. Further data in support of the autoimmune basis of T1D from many fields, including genetics, experimental therapies and immunology, is discussed. Finally, we highlight some of the persistent questions relating to the pathogenesis of human type 1 diabetes that remain to be answered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.